BioNexus Gene Lab Corp financial data

Symbol
BGLC on Nasdaq
Industry
Services-Medical Laboratories
Location
10 2 Tower B, Vertical Business Suite,, 8 Jalan Kerinchi,, Kuala Lumpur, Malaysia
State of incorporation
WY
Fiscal year end
December 31
Former names
BioNexus Gene Lab Coporation (to 5/8/2020)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 502 % +53.8%
Quick Ratio 68.2 % +11.6%
Debt-to-equity 18.1 % -35.7%
Return On Equity -23.1 % -155%
Return On Assets -19.5 % -183%
Operating Margin -22.8 % -362%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18M shares +1.52%
Common Stock, Shares, Outstanding 17.7M shares -89.8%
Entity Public Float 66.5M USD
Common Stock, Value, Issued 17.2M USD +57.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.18M USD -11.3%
Cost of Revenue 7.91M USD -12.2%
General and Administrative Expense 4.47M USD +98.6%
Operating Income (Loss) -2.09M USD -309%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.11M USD -303%
Income Tax Expense (Benefit) -97.2K USD -49.5%
Net Income (Loss) Attributable to Parent -2.21M USD -292%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.84M USD -25.5%
Inventory, Net 1.03M USD -11.4%
Assets, Current 7.84M USD +50.1%
Property, Plant and Equipment, Net 1.35M USD -3.51%
Operating Lease, Right-of-Use Asset 242K USD +438%
Assets 11.1M USD +41%
Accounts Payable, Current 955K USD -47.6%
Liabilities, Current 1.4M USD -25.4%
Deferred Income Tax Liabilities, Net 11.9K USD -59%
Operating Lease, Liability, Noncurrent 183K USD +516%
Liabilities 1.59M USD -17.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -885K USD -13.1%
Retained Earnings (Accumulated Deficit) -1.75M USD -311%
Stockholders' Equity Attributable to Parent 9.55M USD +70.7%
Liabilities and Equity 11.1M USD +41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.4K USD +70.4%
Net Cash Provided by (Used in) Financing Activities 24.2K USD
Net Cash Provided by (Used in) Investing Activities 24.1K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 17.7M shares +22%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -97.2K USD +33.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.41M USD +208%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.66K USD +90.6%
Depreciation 20.1K USD -3.63%
Payments to Acquire Property, Plant, and Equipment 102 USD -99.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.31M USD -169%
Property, Plant and Equipment, Gross 2.31M USD +2%
Operating Lease, Liability, Current 53.2K USD +231%
Deferred Income Tax Expense (Benefit) 16K USD +886%
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital -5.01M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 34.6K USD +103%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 0 USD -100%
Operating Leases, Future Minimum Payments, Due in Three Years 30.3K USD +170%
Operating Leases, Future Minimum Payments Due 133K USD +135%
Interest Expense 4.66K USD +90.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares